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Recent studies on patients who have maintained stable 
hepatic and renal allograft function for 10-28 vears have 
revealed systemIc microchimerism in all (1. 2l. With the be-
lief that this is the essential mechanism of allograft accep-
tance. we sought to augment the spontaneous chimerism in 
newly transplanted recipients. and began a program of com-
bined simultaneous kidney/bone marrow transplantation 
without pretransplant radiation or other cytoreduction 
therapy (3), Postoperative immunosuppression was with 
FK506 and prednisone. using these drugs in the same way as 
in standard practice (4). 
Seventeen cadaver kidney recipients were entered into the 
bone marrow augmentation series up to .June 1994. All are 
well. We report here the first 10. whose simultaneous kidney-
bone marrow transplantations were between December 14. 
1992 and December 14. 1993. '!\vo of them also received pan-
creatic islets. The mean recipient age was 41.32: 13.7 years 
(range 24.6-ti3.4). All patients were undergoing their first 
transplantatIOn and had a panel-reactive antibodv level of 
less than 150. The mean number of HLA matches' and mis-
matches was zAc: 1.3 (range 1-5) and 3.22: 1.8 (range 1-6\. 
respectively. The mean donor age was :25.02:7.5 vears. and 
the mean cold ischemia time was 26.52:9.4 hr. -
Eight control patients undergoing their first cadaveric kid-
ney transplantation but not receiving bone marrow were also 
studied. The most common reason for not performing the 
combined procedure in the control cases was refusal of the 
donor family to consent to vertebral body recovery. Their 
mean age was 44.02:11.0 years (range 29.7-59.8). The mean 
number of HLA matches and mismatches was 3.5:!: 1.9 (range 
1-til and 2.4c:2.0 (range O-Sl. The mean donor age was 50.32: 
12.4 years. and the mean cold ischemia time was 31.32:3.6 hr. 
Neither Irradiation nor any other kind of recipient precon-
ditiOnIng was used in the bone marrow recipients. All blood 
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transfusions. if needed, were with irradiated packed red 
blood cells. After completion of the renal transplant proce-
dure. 3 x lOH unmodified bone marrow cellslkg, isolated from 
the donor vertebral bodies. were infused via central line (3). 
Bone marrow infusion was performed at the time of closure of 
the transplant incision. or shortly thereafter in the recovery 
room. In the 2 patients who received islets. isolation was 
according to previously described techniques (5), The islets 
were infused into the portal vein. after completion of the 
kidney transplant. All of the protocols were approved by the 
Institutional Review Board of the University of Pittsburgh. 
Just prior to transplantation. 40 ml of blood was drawn and 
placed in heparinized tubes. Postoperatively, blood was 
drawn weekly for the first month. and monthly thereafter. for 
chimerism studies. which included fluorescent activated cell 
sorter analysis (FACS), polymerase chain reaction (PCR), 
and V-chromosome analysis by both competitive PCR (cPCR) 
and fluorescent in-situ hybridizatIOn 1 FISH) of cytospin 
samples (in the case of female recipients of kidneys from the 
male donors!. 
The mean follow-up for the 10 kidnev/bone marrow recipi-
ents is 9.92:4.7 months: all are alive and well. and all have 
functioning allografts. The mean serum creatinine and BUN 
are 1.62:0.4 mg/dl. and 232:8 mg/dl. Five (50%) patients have 
been weaned off steroids. The two islet recipients remain on 
insulin: they both have evidence of C-peptide production 
10.44 and 0.11 pmoVml). but at levels insufficient to allow for 
insulin independence. '!\vo (20%) patients experienced early 
kidney non function and required dialysis during the first 
postoperative week. The incidence of acute rejection was 50% 
15 patients). All rejection episodes were responsive to steroids 
andlor an increase in the FK 506 dosage. No patient required 
antilymphocyte therapy. Cytomegalovirus ICMV) was seen in 
2 (20'7c) patients and was treated successfully with intrave-
nous gancyclovir. Graft vs. host disease 1 GVHD) was not seen 
any patient. 
The control recipients of a kidney only have been followed 
for 4.9::0.5 months: all are alive and have functioning al-
lografts (Table 11. The mean serum creatinine and BUN are 
2.4::: 1.0 mg/dl and 50::32 mgtdl. None of these patients has 
been weaned off prednisone as of yet-however. this is most 
likely related to the relatively short follow-up. '!\vo 1:25%) 
patients had acute tubular necrosis (ATN), although only 1 
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TABLE 1. Summary of clinical course 
Initial function Rejection CMV 
Kidney/bone marrow 
1 ~o No No 
2 Yes Yes No 
:3 Yes No No 
4 Yes No No 
5 Yes Yes Yes 
6 Yes Yes No 
7 Yes No Yes 
8 )1'0 Yes No 
9 Yes Yes No 
10 Yes No No 
8 (80'K) 5 (50%) 2(20%) 
Kidney alone 
1 Yes No No 
2 Yes Yes No 
3 No Yes Yes 
4 Yes No No 
5 Yes Yes Yes 
6 Yes No No 
7 Yes Yes No 
Il No Yes No 
6 I 75('<cl 5 (63'k) 2125'}) 
( 13%) required dialysis during the first week after transplan-
tation. The incidence of acute rejection was 63% (5 patients J. 
All rejections were responsive to steroids and an increase in 
FK506. CMV was seen in 2 (25%) patients; both patients 
were successfully treated with gancyclovir. GVHD was not 
seen. 
In the kidneylbone marrow patients. evidence of chimerism 
was present by at least one of the three modalities in 9 of 9 
(100%) evaluable patients (Table 21. The tenth patient, who 
TABLE 2. Testing for mlcrochimerism 
Kidnl'vlhone marrow 
1 
.) 
:1 
·l 
,S(O 
(1" 
7 
Il 
9 
10 
Kidney alone 
1 
2 
:l 
4 
.') 
(j 
7 
Il 
F'ACS" 
O.9'''r 
2.3<:; 
NAd 
<0.5'7r 
1.3'7c 
3.0'7, 
2.7'7r 
NA 
<0.5('<, 
NA 
NA 
~A 
<.5l/c 
NA 
)l'A 
)l'A 
O'} 
<.5l}-
PCR FISH' 
NA 
"' 1.0% 
NA 
l' 1.4'70 
NA 
NA 
NA 
0.2%" 
0.5% 
0.5% 
, All determInatlOns performed >90 days alter transplantatlOn. 
" Fluorescent In-SItu hybridizatlOn for Y·chromosome was per· 
tiJrmed In female recipients of male organs. 
Also receIved islets. 
, NA: test not performed because of lack of feaSIbility I perfect DR 
match and lack of sex dispanty or availabihtv of antibody to mIs-
matched HLA A. 13 antigens). 
. Chimerism was also detected by compeutive PCR and was found 
to be O.5{"c. 
Serum creatInine BUN FK506 Prednisone 
fmg/dl) fmg/dll fmg/day) fmg/day) 
1.1 19 .36 7.5 
1.3 15 20 12.5 
1.1 22 9 0 
1.5 28 18 2.5 
2.3 37 8 12.5 
1.7 22 24 0 
2.0 11 4 0 
1.9 19 18 10 
1.2 32 4 0 
1.7 28 9 0 
1.6=:0.4 23=:8 15=:10 4.5=:5.5 
1.3 21 12 10 
1.9 39 20 10 
3.5 53 30 7.5 
1.4 22 21 .5 
4.2 96 6 25 
2.2 103 4 12.5 
2.4 33 Il 5 
2.4 :l2 14 7.5 
2.4=:2.0 .')0=:32 14.4.!:8.8 10.3=:6.8 
received a I-B, 2-DR matched same-sex allograft. was not 
evaluable for microchimerism by any of these technologies. 
FACS was positive in 5 of7 patients in whom evaluation was 
feasible. with a range of 0.9-3.0%. PCR for HLA disparities 
was positive in 8 of 8 patients in whom the study could be 
performed (Fig. ll. In the three female recipients of kidneys 
from male donors. Y-chromosome detection by PCR was posi-
tive in all cases and in one, competitive PCR ((j) demon-
strated a concentration of 0.5% donor DNA in PBMCs at 1 
year. Using FISH for V-chromosome detection, a level of 0.2-
1.4% was seen (Fig. 2). 
In the kidney alone patients, 3 of the B patients could not 
be evaluated for microchimerism by any modality, because of 
complete DR matching and lack of donor sex disparity. In the 
[) evaluable patients. :3 (60'7<,) were pOSitive for microchimer-
ism by peR. 1 by HLA disparIty, and 2 by V-chromosome 
analysis. However. FACS failed to detect microchimerism in 
any of 3 evaluable patients by :3 months after transplanta-
tion. 
Donor-specific reactivity could not be accurately assessed 
in 3 of the ten kidney/bone marrow recipients because there 
1 3 7 14 300 c- c+ 
FIGURE 1. Polymerase chain reaction I peR) in a kidney/bone mar· 
row reCipient With a dispanty for HLA-A:29. demonstrating persIs-
tent chimensm. 
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FIGURE 2. Fluorescent in-situ hybridization (FISH) of a cytospin 
preparation of PBMCs of a female recipient of a kidneylbone marrow 
from a male donor: orange represents X-chromosome; green repre-
sents V-chromosome. 
was complete DR-matching and a decreased in vitro immu-
nologic response both pre- and post-transplantation. In the 
other 7 patients studied over time, there was one example of 
donor-specific nonresponsiveness and 2 of decreased donor-
specific responsiveness that waxed and waned (Fig. 3), The 
other 4 patients retained donor-specific responsiveness. Only 
5 of the 8 kidney-alone recipients were evaluable. One of the 
5 has some evidence of decreasing responsiveness. 
These results and those with 7 subsequently treated kid-
ney-bone marrow recipients have shown that kidneylbone 
marrow transplantation is straightforward to perform and is 
safe. There were no examples of GVHD. Stable chimerism 
estimated to be WOO-fold more dense than that occurring 
spontaneously (3) was regularly achieved. It should be em-
phasized that (as was expected) bone marrow infusion did not 
influence the early events after transplantation. The inci-
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FIGURE 3. Serial MLR responses of a kidney/bone marrow recipient. 
dence of acute rejection, the rates of early nonfunction. and 
the number cytomegalovirus infections were similar to those 
seen in patients receiving kidneys alone. However, treatment 
of these early problems was straightforward. After passing 
through this phase of convalescence. which was equally vola-
tile with or without bone marrow augmentation. the more 
densely chimeric cohort of kidney-marrow recipients ap-
peared to be an advantaged group. There was lOOCk patient 
and graft survival. and early completion of steroid weaning in 
half the cases. The full benefit of the chimeric state is ex-
pected to take one or 2 years. or longer. This trial was begun 
with patients undergoing primary transplantation who had 
low PRAs. We are now broadening our indications for kidney/ 
bone marrow transplantation to include candidates undergo-
ing retransplantation and/or those with high PRAs in order 
to assess the utility of adjuvant bone marrow in a more com-
plex transplant setting. 
Historically important clinical attempts to facilitate kidney 
graft acceptance have been reported using adjunctive preop-
erative donor blood transfusions (7) or delayed (by 3 weeks) 
cryopreserved cadaveric donor bone marrow (8, 9). Unlike 
the premises of these earlier trials. our hypothesis was that 
long-term engraftment of the infused donor cells could occur 
without "making space" by host preconditioning, without an 
undue risk of GVHD, and using the same immunosuppres-
sive strategy that fostered the previously unrecognized spon-
taneous development of microchimerism (1-3). The observa-
tions in the kidney recipients herein reported, as well as in 
recipients of livers and hearts (3) are confirmatory of these 
predictions. 
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INDEFINITE SURVIVAL FOLLOWING SMALL INTESTINAL 
TRANSPLANTATION AFTER INTRA THYMIC INJECTION OF THE 
DONOR WITH RECIPIENT-TYPE SPLENOCYTES IN A 
RAT MODELl 
MARTIN L. BLAKELY, DAVID SHAFFER, HIROKI OHZATO, RITA GO'ITSCHALK, WILLEM J. VAN DER WERF, 
AND ANTHONY P. MONAC02 
Division of Organ Transplantatwn. New England Deaconess Hospital. Harvard Medical School. 
Due to multiple toxicities associated with chronic nonspe-
cific immunosuppressive therapy, induction of donor-specific 
unresponsiveness or immune tolerance has long been a goal 
of the transplant community (1 ). Various tolerance induction 
regimens have been devised that administer donor-type an-
tigen to the recipient following brief conditioning in which 
peripheral. immunocompetent lymphoid cells are depleted or 
rendered nonfunctional. Immunologic tolerance induction 
following the intrathymic (i.t.)* injection of a specific antigen 
has been studied extensively recently after it was demon-
strated that islet allografts survive indefinitely in rodents 
treated with brief immunosuppression following the i.t. in-
jection of islets from the same strain (21. The phenomenon of 
immune tolerance following i.t_ injection of an antigen was 
actually reported much earlier in several different models (3, 
-/), The Immune unresponsiveness induced by i.t. injection of 
an antigen has been shown to be donor-specific but not 
tissue-specific-i.e., i.t. injection of various donor-type cells 
can induce unresponsiveness to varying tissue or organ al-
lografts (5, 6). 
Despite intense investigation into the mechanisms in-
volved in tolerance induction following i.t. injection of an 
antigen. several important questions remain to be answered. 
The optimal source of antigen, the optimal timing of admin-
istration and the optimal immunosuppressive regimen. if 
any. are all currently unknown and probably vary depending 
on the model studied. The need for the continued presence 
and influence of the thymus with injected antigen is also 
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unknown, and with currently available transplantation mod-
els it is difficult to assess. 
This report describes a new model in which we examine 
tolerance induction following i.t. injection of an antigen with 
the goal of providing new insights into the basic mechanisms 
involved in this type tolerance. We viewed the phenomenon of 
i.t. tolerance induction in a reciprocal fashion with respect to 
the current rejection models following transplantation. Our 
studies show that i.t. injection of recipient-type antigen into 
the donor following a single dose of antilymphocyte serum 
(ALS), in a unidirectional graft-versus-host disease (GVHDl 
model of small bowel transplantation (SBT) in the rat. results 
in specific unresponsiveness of donor-type lymphocytes 
against recipient-type antigen. This unresponsiveness is 
demonstrated by complete elimination of GVHD. which al-
lows indefinite survival of untreated recipients of small bowel 
allografts in this model. 
Lewis rats. either pretreated or naive. served as small 
bowel donors and (Lewis x Brown Norway) F\ hybrid 
(LBNF1) rats were used as recipients. This model ofSBT is a 
unidirectional model in which only GVHD occurs (7). In an 
attempt to "tolerize" the donor lymphocytes against recipi-
ent-type antigen the donors were treated prior to graft har-
vest and transplantation. The six treatment groups are sum-
marized in Table l. Rabbit antirat ALS was given at a dose of 
1 ml by intraperitoneal injection on day -14 relative to graft 
harvest and SBT on day O. On day -9. Lewis donors were 
briven splenocytes (se) from different rat strains (depending 
on the experimental group) by direct i.t. injection of 50x 10" 
cells in 0.1 ml RPMI medium; each thymiC lobe received half 
the total dose. Following this donor pretreatment regimen. 
Lewis small bowel grafts were transplanted heterotopically 
into untreated LBNF t recipients as previously described (8), 
Recipients were weighed daily and assessed for clinical signs 
of GVHD. At the time of death, transplanted intestine. native 
small intestine. spleen. and skin biopsies were examined by 
routine histology to confirm the diagnosis of GVHD. Statis-
tical analysis of survival data was performed by the Kaplan-
